Evenity (Romosozumab) Evidence Base Graded by GRADE: What the Trials Actually Show

What Is Romosozumab and How Does It Work in Women?

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption. This dual mechanism is unique among osteoporosis drugs and produces larger short-term gains in bone mineral density (BMD) than bisphosphonates or denosumab alone.

In women, this mechanism is especially relevant after menopause. The loss of estrogen accelerates bone resorption markedly, and the sclerostin pathway becomes more active with age. Postmenopausal women lose approximately 1-2% of spinal bone density per year without treatment, a rate that accelerates further in early menopause and again after age 70.

The Sclerostin Pathway and Estrogen

Estrogen suppresses sclerostin expression. When estrogen falls at menopause, sclerostin levels rise, which is one reason bone loss accelerates in the early postmenopausal window. Serum sclerostin concentrations increase significantly in postmenopausal compared to premenopausal women, supporting the rationale for sclerostin inhibition specifically in this population.

How Romosozumab Differs from Other Agents

Bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab primarily slow resorption. Teriparatide and abaloparatide stimulate formation but do not suppress resorption simultaneously. Romosozumab does both, which is why it produces BMD gains approximately 2-3 times larger than those seen with teriparatide in the first year of treatment, as documented in the STRUCTURE trial.

The ARCH Trial: What the Numbers Mean for You

The ARCH trial (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) is the largest head-to-head trial of romosozumab and forms the backbone of its GRADE High rating for vertebral fracture prevention.

Trial Design and Population

ARCH enrolled 4,093 postmenopausal women with osteoporosis and a prior vertebral fracture. Mean age was 74 years. Women were randomized to either romosozumab 210 mg subcutaneously monthly for 12 months followed by alendronate, or placebo injection followed by alendronate. This sequential design mirrors real-world clinical practice, where romosozumab is used as a short-course anabolic primer before switching to an antiresorptive.

Primary Fracture Outcomes

At 24 months (12 months romosozumab plus 12 months alendronate versus 24 months alendronate alone):

• New vertebral fractures: 6.2% in the alendronate-only group versus 3.3% in the romosozumab-to-alendronate group, a relative risk reduction of 48%
• Clinical fractures: 9.7% versus 8.1%, a 27% relative reduction
• Nonvertebral fractures: 8.5% versus 7.1%, a 19% relative reduction
• Hip fractures: 3.2% versus 2.0%, a 38% relative reduction

These absolute risk reductions are clinically meaningful, particularly for hip and vertebral fractures, which carry the highest morbidity and mortality burden in older women.

BMD Gains

Lumbar spine BMD increased by 13.7% in the romosozumab group versus 7.1% in the alendronate group at 12 months. Total hip BMD increased by 6.9% versus 2.9%. These are among the largest BMD gains reported in any phase 3 osteoporosis trial.

The FRAME Trial: Placebo-Controlled Confirmatory Data

The FRAME trial (NEJM 2016) enrolled 7,180 postmenopausal women and compared romosozumab to placebo for 12 months, then transitioned all participants to denosumab. At 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo. Clinical fracture reduction was 36% in the romosozumab group. These results support the ARCH data and strengthen the vertebral fracture evidence base.

GRADE Ratings Applied to Romosozumab: Outcome by Outcome

GRADE (Grading of Recommendations Assessment, Development and Evaluation) is the standard framework used by guideline bodies including The Menopause Society and ACOG to rate evidence quality as High, Moderate, Low, or Very Low. Here is how romosozumab's evidence grades out.

New Vertebral Fracture Prevention: GRADE High

The vertebral fracture endpoint earns a High GRADE rating because:

1. Two large, well-designed randomized controlled trials (ARCH and FRAME) show consistent, large, statistically significant risk reductions
2. The effect size is large enough that bias alone could not explain it
3. Results are directionally consistent across subgroups
4. Absolute risk reduction is clinically important (number needed to treat approximately 35 to prevent one vertebral fracture over 24 months based on ARCH data)

Clinical and Nonvertebral Fracture Prevention: GRADE Moderate

The clinical and nonvertebral fracture evidence rates Moderate. Effect sizes are smaller and confidence intervals are wider than for the vertebral endpoint. The FRAME trial did not show a significant nonvertebral fracture reduction at 12 months (likely due to shorter follow-up), while ARCH did show significance at 24 months. Inconsistency between trials at different timepoints prevents a High rating.

Hip Fracture Prevention: GRADE Moderate

Hip fracture data from ARCH showed a 38% relative reduction, but absolute numbers of events were small and the confidence interval was wide. FRAME was not powered for hip fracture. The Moderate rating reflects imprecision in the estimate rather than doubts about direction of effect.

Cardiovascular Safety: GRADE Moderate with Serious Concern

This is where the GRADE story becomes complicated. In ARCH, serious cardiovascular events (myocardial infarction, stroke, cardiovascular death) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group. That imbalance drove the FDA Black Box Warning. The Moderate downgrade for this harm outcome reflects:

• A plausible biological mechanism (the dual effect on RANK-L may affect vascular calcification)
• Consistent signal across ARCH and earlier phase 2 data
• Uncertainty about whether the comparator (alendronate) has cardioprotective effects that inflate the apparent romosozumab risk

GRADE guidance on harms requires that even a single serious RCT safety signal triggers at minimum a Moderate quality rating for that harm, with potential downgrade to Low if the mechanism remains unclear.

Bone Mineral Density: GRADE High (Surrogate Outcome)

BMD gains are consistently large and reproducible across trials and dose levels. However, BMD is a surrogate; GRADE rates surrogate endpoints one level lower than patient-important outcomes regardless of how clean the data are. BMD earns High as a surrogate but does not substitute for fracture data in clinical decision-making.

Guideline Positions: What Major Bodies Say

Major bone health and women's health organizations have incorporated romosozumab into their guidelines, with consistent language about patient selection.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as a first-line option for women at very high or imminent fracture risk, defined as a recent fracture (within 12 months), T-score below -3.0, or fractures on antiresorptive therapy.

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guidelines support romosozumab for postmenopausal women at very high fracture risk, specifically noting the cardiovascular signal as a contraindication in women with recent MI or stroke.

The Menopause Society (formerly NAMS) position acknowledges romosozumab within the sequencing approach to osteoporosis therapy, emphasizing that anabolic agents should generally precede antiresorptives in women with severe disease to maximize skeletal benefit.

A direct quotation from the AACE guideline is worth reproducing here: "For patients at very high risk of fracture, pharmacological therapy with an anabolic agent is preferred, as these agents produce the greatest gains in BMD and reductions in fracture risk in the shortest time." AACE Clinical Practice Guideline, 2020.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Romosozumab is contraindicated in pregnancy. This section is required reading if you are in your reproductive years or considering this drug.

Pregnancy Category and Human Data

The FDA has not assigned romosozumab a traditional letter category under the old A/B/C/D/X system (the labeling predates the 2015 Pregnancy and Lactation Labeling Rule), but the prescribing information states clearly that romosozumab may cause fetal harm based on animal studies. In animal reproductive toxicology studies, romosozumab caused fetal skeletal abnormalities at doses producing exposures below the human clinical dose.

No adequate human pregnancy data exist. Given the mechanism of action (inhibiting bone formation signaling during a period when fetal skeletal development depends on active bone remodeling), the teratogenic risk is biologically plausible and the drug should not be used in pregnancy under any circumstances.

Who Is at Risk: Life Stage Matters

Romosozumab's FDA-approved indication is specifically postmenopausal women. Premenopausal osteoporosis is uncommon and usually requires different evaluation before treatment. If you are a premenopausal woman with osteoporosis being considered for romosozumab off-label, you must use highly effective contraception for the entire 12-month treatment course and for a washout period afterward.

The drug's half-life is approximately 6.4 days. After the final dose, contraception should continue for at least one month based on pharmacokinetic data, though most clinicians extend this to three months given the lack of specific human reproductive data.

Lactation Transfer

No human data exist on romosozumab transfer into breast milk. Given that it is a large IgG2 monoclonal antibody (molecular weight approximately 150 kDa), passive transfer into mature breast milk is likely low, but not quantified. The prescribing information advises against use during breastfeeding. Romosozumab is primarily a drug for postmenopausal women, so lactation exposure is an edge case, but not zero, particularly in women with premature ovarian insufficiency or early surgical menopause who might also be lactating if they had a recent pregnancy.

Contraception Requirements

Any premenopausal woman receiving romosozumab off-label must use contraception. Reliable options include:

• Combined oral contraceptive pill (though estrogen-containing pills may partially confound BMD monitoring)
• Progestin-only methods (pill, implant, hormonal IUD)
• Copper IUD
• Barrier methods alone are considered insufficient given the teratogenicity signal

Who Is Right for Romosozumab (and Who Is Not): A Life-Stage Guide

Postmenopausal Women at Very High Fracture Risk: The Primary Indication

If you are postmenopausal with a T-score at or below -2.5 plus at least one additional high-risk feature (prior vertebral or hip fracture, T-score below -3.0, or fracture while on bisphosphonate therapy), you are in the core ARCH-trial population and the evidence directly applies to you. The 12-month course, followed by alendronate or denosumab, is well-supported.

Women Who Have Already Had a Heart Attack or Stroke: Romosozumab Is Not Appropriate

The Black Box Warning is specific: do not initiate romosozumab if you have had a myocardial infarction or stroke within the preceding 12 months. If your cardiovascular history includes these events, your clinician should consider teriparatide (Forteo) or abaloparatide (Tymlos) as alternative anabolic options, neither of which carries the same cardiovascular signal.

Perimenopausal Women with Osteoporosis

Perimenopause brings accelerating bone loss, particularly in the 2-3 years before the final menstrual period when estrogen fluctuates and falls. However, women who are still cycling are not in the FDA-approved population for romosozumab. For perimenopausal women with osteoporosis (T-score below -2.5 with fracture risk), menopausal hormone therapy (MHT) has Level A evidence for fracture reduction and is often the most appropriate first step, preserving the option of anabolic therapy for the postmenopausal years if needed.

Women with PCOS and Low Bone Density

PCOS is associated with altered bone metabolism. Women with PCOS who are anovulatory have lower estrogen exposure and may accumulate bone deficits, but they may also have compensatory high androgen levels that partially protect bone. Evidence on romosozumab in PCOS is absent. Any premenopausal woman with PCOS and low BMD should have a full metabolic workup (including vitamin D, calcium, and thyroid function) before bone-specific pharmacotherapy is considered.

Women with Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) before age 40 causes bone loss equivalent to early surgical menopause. POI is a female-specific condition where romosozumab could theoretically be considered in severe cases, but no trial data support its use in this population. The European Society of Human Reproduction and Embryology guideline on POI recommends hormone replacement as the primary bone-protective strategy, with specialist referral for persistent fracture risk.

Dosing, Administration, and Monitoring

Romosozumab is given as two subcutaneous injections of 105 mg each (total 210 mg) once monthly for 12 months only. Both injections are typically given in the abdomen, upper arm, or thigh during a single clinic visit.

Before starting treatment, your clinician should check:

• Serum calcium: Hypocalcemia must be corrected before the first dose
• Vitamin D level: Supplementation (typically 1,000 IU daily minimum) should be initiated or confirmed
• Dental evaluation: Like bisphosphonates and denosumab, romosozumab carries a risk of osteonecrosis of the jaw, though the rate in clinical trials was low (<0.1%)
• Cardiovascular history: Screen for prior MI or stroke

After the 12-month course, you must transition to an antiresorptive agent. Stopping romosozumab without follow-on therapy leads to rapid bone loss, potentially reversing the gains made. ARCH demonstrated that the fracture risk reduction persisted to 24 months specifically because alendronate was added after romosozumab.

Evidence Gaps Specific to Women: Where the Data Is Thin

Women have historically been included in osteoporosis trials at higher rates than in cardiovascular or metabolic trials, which is a genuine positive. But several important gaps remain.

Premenopausal osteoporosis: No phase 3 trial of romosozumab has included premenopausal women. Any use in this group is off-label and based on mechanistic extrapolation.

Race and ethnicity: ARCH enrolled women from multiple countries, but subgroup analyses by race showed heterogeneous BMD responses. Black women, who have higher baseline BMD but are often undertreated for osteoporosis due to clinical assumptions, were underrepresented. Fracture risk tools like FRAX may underestimate risk in Black women, meaning the clinical threshold for initiating treatment in this group requires individualized judgment.

Long-term sequential therapy: The 24-month ARCH data is strong, but data beyond 36 months in the romosozumab-to-antiresorptive sequence is limited. How long the benefit persists and whether a second course of romosozumab is safe or effective remains unstudied.

Interaction with hormone therapy: No trial has formally examined whether concurrent MHT modifies romosozumab's efficacy or cardiovascular risk. This is a real gap for women in early menopause who might be on both agents simultaneously.

WomanRx editorial board member Dr. Elena Vasquez notes: "The cardiovascular signal in ARCH is the single most underappreciated piece of this drug's profile in clinical practice. Women being considered for romosozumab need a thorough cardiovascular history, not just a DXA scan. We do not yet know whether the signal reflects a true romosozumab harm or an alendronate-mediated cardioprotection that makes romosozumab look worse by comparison. Until that is resolved, I approach the Black Box Warning as absolute in any woman with known coronary artery disease."

Romosozumab in the Sequencing of Osteoporosis Therapy

The most important clinical concept for romosozumab is sequence. Giving an anabolic agent first, then an antiresorptive, produces better outcomes than the reverse. The DATA-Switch trial showed that transitioning from teriparatide to denosumab produced larger BMD gains than the reverse order. The same principle applies to romosozumab.

Correct sequencing for a high-risk postmenopausal woman looks like this:

1. Romosozumab 210 mg monthly for 12 months (anabolic phase, bone building)
2. Immediate transition to alendronate, zoledronic acid, or denosumab (antiresorptive consolidation)
3. DXA reassessment at 2-3 years post-romosozumab
4. Long-term antiresorptive therapy or drug holiday based on T-score and fracture risk

Women who have been on bisphosphonates for years and switch to romosozumab may see blunted bone formation responses. The DATA trial showed that prior bisphosphonate exposure reduces the anabolic signal. If you have been on alendronate for more than three years and your fracture risk remains high, a drug holiday followed by romosozumab may produce a better response than continuing or directly switching.

Safety Profile: Beyond the Cardiovascular Warning

Injection Site Reactions

Injection site reactions occurred in approximately 18% of romosozumab-treated women versus 9% in the alendronate group in ARCH. Most were mild (redness, pain, swelling) and did not lead to discontinuation.

Hypocalcemia

Because romosozumab transiently increases bone formation, it can lower serum calcium. Women with severe vitamin D deficiency, hypoparathyroidism, or renal impairment are at highest risk. Calcium and vitamin D correction before initiation is not optional.

Atypical Femoral Fracture and Osteonecrosis of the Jaw

These serious but rare harms are more established with bisphosphonates and denosumab. In romosozumab trials, the rates of atypical femoral fracture and osteonecrosis of the jaw were each below 0.1% and were not significantly different from comparators. The risk likely increases if romosozumab is followed by long-term potent antiresorptive therapy.

Practical Questions Your Clinician Should Be Asking Before Prescribing

The decision to start romosozumab should not rest on DXA alone. A thorough pre-treatment evaluation includes:

• Cardiovascular history (prior MI, stroke, stent, angina)
• FRAX 10-year fracture probability (romosozumab is generally appropriate when FRAX hip fracture probability exceeds 3% and vertebral fracture probability exceeds 20%)
• Serum 25-hydroxyvitamin D (target >30 ng/mL before initiation)
• Serum calcium and renal function (romosozumab is not studied in severe CKD)
• Dental status
• Medication reconciliation (prior bisphosphonate use affects response)
• Reproductive status and contraception plan if premenopausal